Ongoing or current autoimmune disease. Permanent but stable and manageab le immune related adverse events (irAE) from prior therapies are permissible, if prednisone equivalent corticosteroid use does not exceed 10 mg/day. 7. Any other condition requiring concurrent systemic immunosuppressive therapy (other than allowable exception s which do not exceed 10mg/day of prednisone/corticosteroid use). 8. Major surgery (requiring general anesthesia or inpatient hospitalization) within four weeks before first IMP administration. 9. Any ongoing anticancer therapy including; small molecules, immuno therapy, chemotherapy, monoclonal antibodies , radiation (curative/treatment intent) or any other experimental drug. Prior therapy must be stopped within four weeks before first infusion in the study, or 5 half -lives, or twice the duration of the biologica l effect of the investigational product (whichever is shortest). Adjuvant anti-hormonal treatment(s) for previously treated breast cancer or prostate cancer are allowed. Bisphosphonates are allowed, Denosumab and other RANK ligand inhibitors are prohibited . Note that palliative radiation only requires a two week washout. 10. Known current malignancy other than inclusion diagnosis. Prior curable cancer with complete remission for >2 years is allowed. 11. Any other ongoing significant, uncontrolled medical condition as per Investigator discretion . 12. Received a live vaccine within 30 days prior to first dose of study drug. 13. Clinically significant active viral, bacterial or fungal infection requiring: a. Intravenous treatment with antimicrobial therapy completed less than two weeks prior to first dose, or b. Oral treatment with antimicrobial therapy completed less than one week prior to first dose. Prophylactic treatment with antibiotics (e.g. for dental extractions) is allowed. 14. Known positive serology for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C (except in cases of immunity after cured infection). Testing not required.